Recently, Tolar et al.
1 described four cases of Wolman's disease treated with SCT. In this report, a relatively high mortality rate (2/4) was noted, with the deaths attributed to sinusoidal obstruction syndrome (SOS), multi-organ failure and sepsis in the first case, and hepatic failure and sepsis in the second case.
We report a case of Wolman's disease unsuccessfully treated with SCT at our institution with similar complications of hepatic failure, but determined to be secondary to progressive Wolman's disease rather than SOS. A full-term female infant was admitted on day 50 of life for failure to thrive, presenting with chronic diarrhea, abdominal distension and hepatosplenomegaly. Renal ultrasound identified adrenal calcifications, and analysis of peripheral blood leukocytes showed deficient leukocyte acid lipase (LAL) enzyme activity of 2 pmol/min per mg protein (normal range 20-200 pmol/min per mg protein). Genetic sequence analysis showed compound heterozygosity in the LAL gene, which, together with enzymatic testing, confirmed the diagnosis of Wolman's disease.
The patient was then started on total parenteral nutrition with minimal fatty acid supplementation in an effort to mitigate further organ damage. In the absence of a matched related donor, a 10/10 HLA-matched unrelated male donor was rapidly identified. Because of pronounced hepatomegaly and concern for risk for hepatic SOS, the patient received reduced-intensity conditioning consisting of BU 37.5 mg/m 2 i.v. on days À9, À8, À7 and À6 with a targeted area under the blood busulfan concentration vs time curve of 1100 mmol/min, fludarabine 35 mg/m 2 i.v. on days À9, À8, À7 and À6, reduced-dose CY 35 mg/kg i.v. on days À5, À4 and À3, and Alemtuzumab 12 mg/m 2 on day À5, 20 mg/m 2 on days À4 and À3. GVHD prophylaxis included Tacrolimus, MTX and Alemtuzumab. SCT was carried out on day 85 of life. Myeloid engraftment occurred on day þ 22 post-SCT. Variable nucleotide tandem repeat chimerism analysis indicated donor engraftment and normal peripheral LAL enzyme activity was detected (see Table 1 ). However, the patient developed gradual increases in bilirubin, liver enlargement, massive ascites and renal failure. On day þ 49 post-SCT, an abdominal ultrasound indicated reversed portal flow, suggesting hepatic SOS. Candida parapsilosis sepsis, combined with multi-organ failure and vasopressor dependence, led to withdrawal of support on day þ 73 post-SCT, on day 158 of life.
Post-mortem liver wedge biopsy was consistent with Wolman's disease, without histological evidence of GVHD or SOS (Figure 1 ). Intra-hepatic fluorescent in situ hybridization targeting the donor Y chromosome was negative, confirming ongoing presence of host-derived tissue macrophages. Thus, despite evidence of peripheral LAL correction coinciding with marrow engraftment, this patient died from complications of Wolman's disease before donor-derived macrophage engraftment occurred.
SCT presumably corrects LAL deficiency through engraftment of normal donor-derived macrophages. 2, 3 Post-engraftment enzyme transfer is thought to occur either by direct cell-cell contact or by endocytosis of leukocyte-secreted enzymes by deficient recipient tissue cells. 4, 5 Enzyme transfer during tissue engraftment permits catabolism of accumulated fats, with theoretical remodeling of the damaged organs. 6 In other human metabolic diseases such as Gaucher's disease, engraftment after SCT has been shown to rapidly normalize peripheral leukocyte enzyme activity; but significantly more time is required to clear marrow Gaucher cells and hepatic lysosomal storage material, as well as correct plasma enzymatic levels. 7 Similarly, in patients with mucopolysaccharidoses receiving SCT, hepatocyte and Kupffer cell clearance of glycosaminoglycans is also delayed, occurring between 3 and 19 months post-SCT. 8 The discrepancy between peripheral leukocyte correction and development of donor-derived tissue macrophages is a critical, generalizable principle applying to SCT for metabolic disease. Length of time to correction of enzymatic deficiency in recipient tissues may be from 3 months up to a year, during which ongoing damage from the underlying defect occurs. Early onset of irreparable organ damage in Wolman's disease, combined with evidence for ongoing damage for several months even after transplant, predicts poor survival with significant risk for organ toxicity. Given the variety of LAL mutations described in Wolman's disease, an additional variable affecting outcome may be the severity of the metabolic abnormality caused by residual recipient-derived macrophages. Continued documentation of mutation analyses and clinical course of this disease may enable eventual prediction of risk and chance for success in SCT.
Worsening hepatomegaly because of progressive Wolman's disease is difficult to distinguish clinically from SOS, as observed in our case and perhaps explaining the apparent SOS suffered by patient 2 in Tolar et al. 1 We propose that liver biopsy may be the only method of differentiating the hepatic effects of Wolman's disease from SOS post-SCT. Experience with SCT is currently too limited to determine whether either mutation analysis or degree of underlying hepatic pathological damage observed pre-SCT is predictive of clinical outcome.
Despite rare reports of long-term successes such as noted in Tolar et al., 1 Wolman's disease remains near-universally fatal. Curing this disease with SCT is extremely challenging, with the majority of attempts resulting in death because of liver failure from progressive Wolman's disease or SOS, as well as other transplant-related complications including infection, GVHD and failure to engraft. 9 Presently, there are no proven strategies to accelerate the differentiation and engraftment of donor-derived macrophages in an SCT recipient. Development of such strategies would contribute significantly to reducing mortality in this disease. 
MM Gramatges

